Get the Stockscreener App
17.04
1.25%
0.21
After Hours:
17.40
0.36
+2.11%
Assembly Biosciences Inc Stock (ASMB) Latest News
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Increase in Short Interest - MarketBeat
Assembly Biosciences investor Alexander Schornstein buys $372,994 in shares By Investing.com - Investing.com
Novavax and Assembly lead infectious disease gainers in 2024 - BioWorld Online
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
Genome Editing Market Size Projected to Reach USD 32.72 - GlobeNewswire
Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances - TipRanks
(ASMB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ARMISTICE CAPITAL, LLC Adjusts Stake in Assembly Biosciences Inc - GuruFocus.com
HC Wainwright Has Optimistic Outlook of ASMB FY2024 Earnings - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 51.2% in October - MarketBeat
Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers - Simply Wall St
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates - Yahoo Finance
Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World
Assembly Biosciences: Q3 Earnings Snapshot - CTPost
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences initiates at-the-market equity program - Investing.com India
Assembly Biosciences Inc (ASMB) Reports Q3 2024 Revenue of $6.8M, GAAP EPS Loss of $1.51, Misses Estimates - GuruFocus.com
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
When (ASMB) Moves Investors should Listen - Stock Traders Daily
Baker Lab’s AI-Driven Antibody Cage Technology Unlocked as Archon Biosciences - Genetic Engineering & Biotechnology News
Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Declines By 7.9% - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
(ASMB) Investment Analysis and Advice - Stock Traders Daily
Microbiome Manufacturing Market Poised for Robust Growth at 15.4% CAGR by 2031 - WhaTech
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update - MarketBeat
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) market cap surged US$16m last week, individual investors who have a lot riding on the company were rewarded - Simply Wall St
Assembly Biosciences sees major stock purchase by investor Alexander Schornstein By Investing.com - Investing.com Canada
Alexander Schornstein Purchases 10,000 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences CEO sells shares worth $2,917 to cover taxes By Investing.com - Investing.com South Africa
Assembly Biosciences CEO sells shares worth $2,917 to cover taxes - Investing.com India
How To Trade (ASMB) - Stock Traders Daily
Assembly Biosciences executive sells shares worth $2,325 By Investing.com - Investing.com South Africa
Assembly Biosciences executive sells shares worth $2,325 - Investing.com India
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Growth in Short Interest - MarketBeat
Armistice Capital LLC Makes New Investment in Assembly Biosciences, Inc. (NASDAQ:ASMB) - MarketBeat
Investment Analysts’ Updated EPS Estimates for September 24th (AB, AG, AIOT, AIR, AMWL, ASMB, BAG, BDTX, BHVN, BIIB) - Defense World
Assembly Biosciences (NASDAQ:ASMB) Rating Reiterated by HC Wainwright - MarketBeat
(ASMB) Trading Signals - Stock Traders Daily
Assembly Biosciences advances genital herpes treatment study - Investing.com
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants - AOL
Tonight | The Assembly on ABC and ABC iview S1E6 - TV Central
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):